In this issue:
Exercise intensity and AF risk in men and women
AF and CV/renal disease and mortality risks
Death and stroke 1 year after AF
NOACs after cardioversion for nonvalvular AF
Full-dose apixaban in ARISTOTLE participants with one dose-reduction criterion
Anticoagulant use in AF during sepsis
Catheter ablation for AF in hypertrophic cardiomyopathy
Rivaroxaban and dabigatran in Asians with nonvalvular AF
Edoxaban vs. warfarin in AF patients at risk of falling
Adjuvant antiarrhythmic drugs postablation
Please login below to download this issue (PDF)